Researchers from Mass General Brigham will present research discoveries and outcomes from clinical trials in cancer at the ...

Research from the University of Cincinnati reveals how the MYC oncogene alters PRPS enzymes, impacting redox homeostasis and ...

National Institutes of Health (NIH) scientists report that a first-in-human clinical trial of a new therapy based on the ...

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, ...

The Cocoon® (from Lonza) is a functionally closed, sterile, efficient manufacturing platform, which combined with our ...

DelveInsight’s Natural Killer (NK)-Cell Lymphoma Pipeline report depicts a robust space with 100+ active players working to develop 140+ pipeline therapies for Natural Killer (NK)-Cell Lymphoma ...

CD70 expression increased cytotoxicity of CD70 CAR NK cells against osteosarcoma; however, upregulation of CD70 had no effect on cytotoxicity.

Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...

Rui Tostoes, Chief Technology Officer at ImmuneBridge, shares how his team is redefining preclinical development and ...

Manufacturing CAR T cells in the laboratory is expensive and time-consuming. An in vivo approach could get the powerful ...